Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

382 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A double-blind, randomized, controlled multicentre study to compare the efficacy of ciprofloxacin with pivampicillin as oral therapy for epididymitis in men over 40 years of age.
Eickhoff JH, Frimodt-Møller N, Walter S, Frimodt-Møller C. Eickhoff JH, et al. BJU Int. 1999 Nov;84(7):827-34. doi: 10.1046/j.1464-410x.1999.00252.x. BJU Int. 1999. PMID: 10532980 Clinical Trial.
The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol.
Jansåker F, Frimodt-Møller N, Bjerrum L, Dahl Knudsen J. Jansåker F, et al. BMC Infect Dis. 2016 Dec 1;16(1):727. doi: 10.1186/s12879-016-2022-0. BMC Infect Dis. 2016. PMID: 27905884 Free PMC article. Clinical Trial.
Antibiotic selection of Escherichia coli sequence type 131 in a mouse intestinal colonization model.
Hertz FB, Løbner-Olesen A, Frimodt-Møller N. Hertz FB, et al. Antimicrob Agents Chemother. 2014 Oct;58(10):6139-44. doi: 10.1128/AAC.03021-14. Epub 2014 Aug 4. Antimicrob Agents Chemother. 2014. PMID: 25092712 Free PMC article.
Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
Prahl JB, Johansen IS, Cohen AS, Frimodt-Møller N, Andersen ÅB. Prahl JB, et al. J Antimicrob Chemother. 2014 Oct;69(10):2841-7. doi: 10.1093/jac/dku210. Epub 2014 Jun 16. J Antimicrob Chemother. 2014. PMID: 25140577
Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
Christiansen N, Nielsen L, Jakobsen L, Stegger M, Hansen LH, Frimodt-Møller N. Christiansen N, et al. Microb Drug Resist. 2011 Sep;17(3):395-406. doi: 10.1089/mdr.2011.0015. Epub 2011 Jun 13. Microb Drug Resist. 2011. PMID: 21668371
Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.
Jakobsen L, Cattoir V, Jensen KS, Hammerum AM, Nordmann P, Frimodt-Møller N. Jakobsen L, et al. J Antimicrob Chemother. 2012 Oct;67(10):2438-44. doi: 10.1093/jac/dks224. Epub 2012 Jun 8. J Antimicrob Chemother. 2012. PMID: 22685162
Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance.
Jensen US, Muller A, Brandt CT, Frimodt-Møller N, Hammerum AM, Monnet DL; DANRES study group. Jensen US, et al. J Antimicrob Chemother. 2010 Jun;65(6):1286-91. doi: 10.1093/jac/dkq093. Epub 2010 Apr 2. J Antimicrob Chemother. 2010. PMID: 20363806
Antibiotic usage in an intensive care unit in a Danish university hospital.
Røder BL, Nielsen SL, Magnussen P, Engquist A, Frimodt-Møller N. Røder BL, et al. J Antimicrob Chemother. 1993 Oct;32(4):633-42. doi: 10.1093/jac/32.4.633. J Antimicrob Chemother. 1993. PMID: 8288506
382 results
Jump to page
Feedback